Antitumor effect fortifier, antitumor agent and method of therapy for cancer

Abstract

The present invention provides an antitumor effect potentiator, a method for treating cancer using a plurality of pharmaceutical preparations having excellent antitumor activity, and an antitumor preparation. In particular, the present invention provides an antitumor effect potentiator for potentiating the antitumor activity of an antitumor preparation comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for potentiating an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect, the antitumor effect potentiator comprising cis-oxalate( 1R , 2R -diaminocyclohexane)platinum(II) in an amount effective for potentiating the antitumor effect; a method for treating cancer comprising the step of concomitantly administering tegafur in a therapeutically effective amount, gimeracil in an amount effective for potentiating an antitumor effect, oteracil potassium in an amount effective for inhibiting a side effect, and cis-oxalate( 1R,2R- diaminocyclohexane)platinum(II) in an amount effective for potentiating the antitumor effect; an antitumor preparation in a pharmaceutical form comprising a plurality of pharmaceutical agents each of which contains one of the active ingredients consisting of tegafur, gimeracil, oteracil potassium, and cis-oxalate( 1R , 2R -diaminocyclohexane)platinum(II), or each of which contains such active ingredients in any combination, or in a pharmaceutical form comprising a single pharmaceutical agent containing all the active ingredients; and a kit.

Description

technical field [0001] The present invention relates to an antitumor effect enhancer; a cancer treatment method for enhancing antitumor effect by novel combination administration of antitumor agents; an antitumor agent; and a kit for cancer treatment. Background technique [0002] Research and development of antitumor agents have been actively carried out. Many effective antineoplastic agents are clinically used to treat malignant tumors. For example, tegafur is an agent that is activated in vivo and gradually releases an active ingredient (ie, 5-fluorouracil (hereinafter referred to as "5-FU")), thereby reducing toxicity and side effects produced by 5-FU. [0003] Such a compound pharmaceutical agent of tegafur and uracil (trade name: UFT, tegafur / uracil molar ratio of 1:4, manufactured by Taiho Pharmaceutical Co. Ltd.) is known. This complex exhibits a significant antitumor effect because uracil, which alone does not have any antitumor effect, inhibits the inactivation o...

AI Technical Summary

Problems solved by technology

FOLFOX therapy is complicated to operate, so there are problems such as low quality of life (QOL) of patients and high medical expenses caused by physical constraints accompanied by continuous infusion